Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and|[sol]|or transplant-ineligible patients with multiple myeloma: a meta-analysis

P Kapoor; S V Rajkumar; A Dispenzieri; M A Gertz; M Q Lacy; D Dingli; J R Mikhael; V Roy; R A Kyle; P R Greipp; S Kumar; S J Mandrekar

首页> 外文期刊>Leukemia >Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and|[sol]|or transplant-ineligible patients with multiple myeloma: a meta-analysis

【24h】

Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and|[sol]|or transplant-ineligible patients with multiple myeloma: a meta-analysis

机译：美法仑和泼尼松与美法仑，泼尼松和沙利度胺治疗老年和[或]不适合移植的多发性骨髓瘤患者的荟萃分析

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Leukemia 》 |2011年第9期| 共2页
作者
P Kapoor; S V Rajkumar; A Dispenzieri; M A Gertz; M Q Lacy; D Dingli; J R Mikhael; V Roy; R A Kyle; P R Greipp; S Kumar; S J Mandrekar;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. [J] . Mateos MV, Oriol A, Martinez Lopez J, The lancet oncology . 2010 ,第10期

机译：对于未经治疗的多发性骨髓瘤老年患者，硼替佐米，美法仑和泼尼松与硼替佐米，沙利度胺和泼尼松作为诱导疗法，然后采用硼替佐米和沙利度胺与硼替佐米和泼尼松维持治疗：一项随机试验。
2. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study [J] . MorabitoF., BringhenS., LaroccaA., American Journal of Hematology . 2014 ,第4期

机译：新诊断的老年多发性骨髓瘤患者中硼替佐米，美法仑，泼尼松（VMP）与美法仑，泼尼松，沙利度胺（MPT）的回顾性病例匹配研究
3. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study [J] . MorabitoF., BringhenS., LaroccaA., American Journal of Hematology . 2014 ,第4期

机译：Bortezomib，Melphalan，泼尼松（VMP）与Melphalan，泼尼松，沙利尼胺（MPT）在老年人新诊断的多发性骨髓瘤患者中：回顾性案例匹配的研究
4. RISK-ADAPTED INTRAVENOUS MELPHALAN WITH ADJUVANT THALIDOMIDE AND DEXAMETHASONE FOR NEWLY DIAGNOSED UNTREATED PATIENTS WITH SYSTEMIC AL AMYLOIDOSIS: INTERIM REPORT OF A PHASE II TRIAL [C] . RL Comenzo, P Zhou, L Reich, International Symposium on Amyloidosis . 2005

机译：风险适应的静脉内莫尔甘蔗用佐剂沙利度胺和地塞米松，用于新诊断的未经治疗的全身淀粉样蛋白症患者：II期试验的中期报告
5. Assessing the Prevalence and Outcomes of Multiple Myeloma Patients with Diabetes [D] . La, Lisa T. 2021

机译：评估多发性骨髓瘤患者糖尿病患者的患病率和结果
6. The Cost-Effectiveness of Initial Treatment of Multiple Myeloma in the U.S. With Bortezomib Plus Melphalan and Prednisone Versus Thalidomide Plus Melphalan and Prednisone or Lenalidomide Plus Melphalan and Prednisone With Continuous Lenalidomide Maintenance Treatment [O] . Louis P. Garrison Jr., Si-Tien Wang, Hui Huang, 2013

机译：硼替佐米加美法仑和泼尼松与沙利度胺加美法仑和泼尼松或来那度胺加美法仑和泼尼松联合来那度胺持续维持治疗的美国多发性骨髓瘤的初始治疗的成本效益
7. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study [O] . Morabito, Fortunato, Bringhen, Sara, Mateos, Maria Victoria, 2016

机译：新诊断的老年多发性骨髓瘤患者中硼替佐米，美法仑，泼尼松（VMP）与美法仑，泼尼松，沙利度胺（MPT）的回顾性病例对照研究

Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and|[sol]|or transplant-ineligible patients with multiple myeloma: a meta-analysis

著录项

相似文献

相关主题

期刊订阅